Department of Pharmacology, School of Pharmacy, Qingdao University Medical College, Qingdao, Shandong, China.
Drug Discov Ther. 2021;15(1):44-47. doi: 10.5582/ddt.2021.01013.
Cancer is still a major factor threatening human life around the world, and anticancer drugs remain a huge unmet clinical need. Here, we reviewed novel drugs including new molecular entities and new therapeutic biologics approved in the US, EU, Japan, and China that represent the main advances in anticancer drug research and development in 2020. Small molecule inhibitors targeting oncogenes, antibodies, and antibody drug conjugates (ADCs) are the main anticancer drugs that were approved in 2020. More novel anticancer drugs that possess target activity and that overcome drug resistance are anticipated in the future.
癌症仍然是全球威胁人类生命的主要因素，抗癌药物仍然是巨大的未满足的临床需求。在这里，我们回顾了 2020 年在美国、欧盟、日本和中国批准的新型药物，包括新的分子实体和新的治疗性生物制剂，这些药物代表了抗癌药物研究和开发的主要进展。针对致癌基因的小分子抑制剂、抗体和抗体药物偶联物（ADC）是 2020 年批准的主要抗癌药物。预计未来会有更多具有靶向活性和克服耐药性的新型抗癌药物。
